Treatment-related leukaemia--a clinical and scientific challenge.

2.50
Hdl Handle:
http://hdl.handle.net/10541/86527
Title:
Treatment-related leukaemia--a clinical and scientific challenge.
Authors:
Ng, Antony; Taylor, G Malcolm; Eden, Tim O B
Abstract:
The development of a second tumour, including treatment-related leukaemia (TRL), is the most devastating complication of intensive cancer chemotherapy. This is especially relevant in the paediatric population as over 70% of children diagnosed with a malignancy will now live at least 5 years. Most TRLs are myeloid leukaemias and carry an overall poor prognosis when compared with their de novo counterparts. Despite the well known association with specific cytotoxic agents, improved understanding of the pathogenesis and risk factors of TRL is ultimately essential if we are to develop successful strategies for prevention and treatment. Here we review these aspects, together with the clinical and diverse biological features of this complication and the efficacy of current therapy.
Affiliation:
Immunogenetics Laboratory, St Mary's Hospital, Hathersage Road, Manchester M13 OJH, UK.
Citation:
Treatment-related leukaemia--a clinical and scientific challenge. 2000, 26 (5):377-91 Cancer Treat. Rev.
Journal:
Cancer Treatment Reviews
Issue Date:
Oct-2000
URI:
http://hdl.handle.net/10541/86527
DOI:
10.1053/ctrv.2000.0186
PubMed ID:
11006138
Type:
Article
Language:
en
ISSN:
0305-7372
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorNg, Antonyen
dc.contributor.authorTaylor, G Malcolmen
dc.contributor.authorEden, Tim O Ben
dc.date.accessioned2009-11-19T17:10:53Z-
dc.date.available2009-11-19T17:10:53Z-
dc.date.issued2000-10-
dc.identifier.citationTreatment-related leukaemia--a clinical and scientific challenge. 2000, 26 (5):377-91 Cancer Treat. Rev.en
dc.identifier.issn0305-7372-
dc.identifier.pmid11006138-
dc.identifier.doi10.1053/ctrv.2000.0186-
dc.identifier.urihttp://hdl.handle.net/10541/86527-
dc.description.abstractThe development of a second tumour, including treatment-related leukaemia (TRL), is the most devastating complication of intensive cancer chemotherapy. This is especially relevant in the paediatric population as over 70% of children diagnosed with a malignancy will now live at least 5 years. Most TRLs are myeloid leukaemias and carry an overall poor prognosis when compared with their de novo counterparts. Despite the well known association with specific cytotoxic agents, improved understanding of the pathogenesis and risk factors of TRL is ultimately essential if we are to develop successful strategies for prevention and treatment. Here we review these aspects, together with the clinical and diverse biological features of this complication and the efficacy of current therapy.en
dc.language.isoenen
dc.subjectLeukaemiaen
dc.subjectSecond Primary Canceren
dc.subjectRadiation-Induced Leukaemiaen
dc.subject.meshAntineoplastic Agents, Alkylating-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshEnzyme Inhibitors-
dc.subject.meshGenetic Predisposition to Disease-
dc.subject.meshHumans-
dc.subject.meshIncidence-
dc.subject.meshLeukemia-
dc.subject.meshLeukemia, Radiation-Induced-
dc.subject.meshNeoplasms, Second Primary-
dc.subject.meshPrognosis-
dc.subject.meshRisk Factors-
dc.titleTreatment-related leukaemia--a clinical and scientific challenge.en
dc.typeArticleen
dc.contributor.departmentImmunogenetics Laboratory, St Mary's Hospital, Hathersage Road, Manchester M13 OJH, UK.en
dc.identifier.journalCancer Treatment Reviewsen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.